Share on StockTwits

Eli Lilly and (NYSE:LLY) major shareholder Lilly Endowment Inc unloaded 190,000 shares of Eli Lilly and stock on the open market in a transaction dated Thursday, June 5th. The stock was sold at an average price of $59.53, for a total value of $11,310,700.00. Following the sale, the insider now directly owns 134,500,804 shares of the company’s stock, valued at approximately $8,006,832,862. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

A number of research firms have recently commented on LLY. Analysts at Morgan Stanley reiterated an “underweight” rating on shares of Eli Lilly and in a research note on Monday. They now have a $48.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly and in a research note on Friday, May 16th. They now have a $61.00 price target on the stock. Finally, analysts at Argus reiterated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, April 29th. They now have a $64.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $60.46.

Eli Lilly and (NYSE:LLY) traded up 0.02% on Friday, hitting $59.59. The stock had a trading volume of 1,092,104 shares. Eli Lilly and has a 1-year low of $47.53 and a 1-year high of $61.15. The stock’s 50-day moving average is $59.35 and its 200-day moving average is $55.79. The company has a market cap of $63.922 billion and a price-to-earnings ratio of 16.65.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.70 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.70. The company had revenue of $4.68 billion for the quarter, compared to the consensus estimate of $4.78 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. The company’s quarterly revenue was down 16.4% on a year-over-year basis. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, June 10th. Stockholders of record on Thursday, May 15th will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.30%. The ex-dividend date of this dividend is Tuesday, May 13th.

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.